Results 171 to 180 of about 75,003 (261)
ABSTRACT Objective To synthesize the evidence on the efficacy and safety of mirabegron and intradetrusor onabotulinumtoxinA (BoNT‐A) as separate interventions for overactive bladder (OAB) in Parkinson's disease (PD). Methods A systematic review and meta‐analysis with parallel synthesis of two distinct interventions was conducted of randomized and ...
Hussain Arshad +4 more
wiley +1 more source
Information Design for Early‐Stage Dose‐Finding Trials
ABSTRACT To enhance enrollment rates in early‐stage dose‐finding clinical trials, we propose an information design approach, where the clinical investigator (CI) commits to an information releasing mechanism (IRM) based on the treatment's uncertain efficacy and toxicity to encourage patients to participate in the trial.
Amin Khademi, Ningyuan Chen
wiley +1 more source
Individuals that disperse typically exhibit specific phenotypical traits that facilitate dispersal and settlement success, known as ‘dispersal syndromes'. Consequentially, characterizing dispersers is crucial to understand other processes such as metapopulation dynamics and biological invasions.
Gilles De Meester +6 more
wiley +1 more source
Dispersal is a key ecological trait that ensures connectivity, gene flow, and range dynamics, yet empirical information about how dispersal distances vary within species remains scarce. Many studies, investigating for instance connectivity conservation, use typical species‐specific dispersal kernels without accounting for the fact that these kernels ...
Jette Wolff +5 more
wiley +1 more source
ABSTRACT Background Intravenous lidocaine therapy (IVLT) is often used in perioperative multimodal analgesia due to its analgesic, anti‐hyperalgesic, and anti‐inflammatory effects. In adults, IVLT doses of 1–2 mg/kg/h produce plasma concentrations of 1–2 μg/mL, within the presumed therapeutic range of 1–5 μg/mL.
McKenna Postles +3 more
wiley +1 more source
Alien hand syndrome: a neurological disorder of will
openaire +1 more source
Abstract Myotonic dystrophy type 1 (DM1) is a clinically challenging multisystem neuromuscular hereditary disorder, with generational increase in severity and earlier age at onset. It is caused by an unstable cytosine‐thymine‐guanine repeat expansion at the DMPK locus, accompanied by associated genetic and epigenetic modifications.
Md Mehedi Hasan +9 more
wiley +1 more source
Pearls & Oy-Sters: Plantar Agraphesthesia in Corticobasal Syndrome. [PDF]
Perkins JA, Price RS, Vizcarra JA.
europepmc +1 more source
Asymmetric Upper Limb Dysfunction Demonstrated at the Bedside: A Phenomenology Video
Movement Disorders Clinical Practice, EarlyView.
Gero Lueg +4 more
wiley +1 more source

